We are happy to announce that the new version of the TED portal is going live on 29.01.2024 (indicative date - to be confirmed!) Interested in discovering the new functionalities, improvements and impact on the users? We invite you to visit our article and find out more about the main new changes and functionalities.

There are some bugs affecting the way eForms notices are displayed. We are working on solving the problem. In the meanwhile, please check our dedicated page for more information and guidance.

Registration is open for our 4th Workshop with TED reusers, on the 14th of December 2023

Services - 589007-2019
12/12/2019    S240

United Kingdom-Salisbury: IT services: consulting, software development, Internet and support

2019/S 240-589007

Prior information notice

This notice is a call for competition

Services

Legal Basis:
Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
Official name: Porton Biopharma
Town: Salisbury
NUTS code: UKK1 Gloucestershire, Wiltshire and Bristol/Bath area
Country: United Kingdom
E-mail: jeff.pike@portonbiopharma.com
Internet address(es):
Main address: https://www.portonbiopharma.com/
I.2)Information about joint procurement
The contract is awarded by a central purchasing body
I.3)Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at: https://portonbiopharma.bravosolution.co.uk
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically via: https://portonbiopharma.bravosolution.co.uk
Tenders or requests to participate must be submitted to the abovementioned address
I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

PBL ICT Infrastructure

II.1.2)Main CPV code
72000000 IT services: consulting, software development, Internet and support
II.1.3)Type of contract
Services
II.1.4)Short description:

Porton Biopharma (PBL) is undertaking an extensive programme of work to create a new ICT core infrastructure, following the approval of a 5-year technical strategy by the business, mid-2019. Beginning with a limited scope ‘Pilot’ phase, the primary hosting and network solutions, cyber-security controls and use-cases must be trialled and refined. The duration of the pilot is expected to be circa 6 months.

II.1.5)Estimated total value
II.1.6)Information about lots
This contract is divided into lots: no
II.2)Description
II.2.3)Place of performance
NUTS code: UKK1 Gloucestershire, Wiltshire and Bristol/Bath area
II.2.4)Description of the procurement:

Porton Biopharma (PBL) is undertaking an extensive programme of work to create a new ICT core infrastructure, following the approval of a 5-year technical strategy by the business, mid-2019. Beginning with a limited scope ‘Pilot’ phase, the primary hosting and network solutions, cyber-security controls and use-cases must be trialled and refined. The duration of the Pilot is expected to be circa 6 months.

Having been fully dependent on Public Health England (PHE) ICT services and infrastructure since its inception in 2015, it is strategically important for PBL to now establish a completely new and independent ICT operation.

The following technical strategy has been approved for implementation. Within the limited scope of a Pilot phase, ICT services organisations are invited to express an interest in designing, supplying and building this environment in close collaboration with a dedicated PBL team, on a fixed-price basis.

— HCI-based hosting platform – currently specified as Dell-EMC VxRail stretch-cluster,

— physical network underlay (limited scope),

— perimeter firewall (to be specified),

— SDN network overlay technology (circa 30 endpoints) – currently specified as Cisco’s SDA solution,

— Horizon VDI for application and desktop virtualisation (2-3 pilot application environments).

— MS Windows domain(s) dedicated to PBL – including all domain-related services and inter-domain trust for testing purposes,

— coherent IDAM/RBAC ecosystem.

The Pilot infrastructure will form the basis of a broader enterprise ICT core infrastructure that will be built-out in subsequent programme phases.

PBL operates within a highly regulated pharmaceutical environment (within FDA and MHRA codes/guidance for GMP IT). Close collaboration with PBL and adherence to ITIL principles and local IT infrastructure qualification controls will be critical to ensure compliance with regulatory standards from day-1.

II.2.5)Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6)Estimated value
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 24
II.2.10)Information about variants
II.2.11)Information about options
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation
III.1.2)Economic and financial standing
Selection criteria as stated in the procurement documents
III.1.3)Technical and professional ability
Selection criteria as stated in the procurement documents

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Restricted procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.2)Time limit for receipt of expressions of interest
Date: 24/01/2020
Local time: 17:00
IV.2.4)Languages in which tenders or requests to participate may be submitted:
English
IV.2.5)Scheduled date for start of award procedures:

Section VI: Complementary information

VI.2)Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Official name: Porton Biopharma
Town: Salisbury
Country: United Kingdom
VI.5)Date of dispatch of this notice:
10/12/2019